Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioequivalence of Dronedarone Hydrochloride in healthy subjects
NCT07396519Phase 1Completed
- Sponsor
- Shandong New Time Pharmaceutical
- Start
- Nov 2022
- Primary completion
- Dec 2022
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of dronedarone in Atrial fibrillation (AFib) (2 arms), sponsored by Shandong New Time Pharmaceutical. Primary endpoints: Peak Plasma Concentration at 72 hours, Area under the plasma concentration versus time curve 0-t at 72 hours and 1 more. Started Nov 2022; status: completed.
02
Drugs
dronedarone
03
Conditions
Atrial fibrillation (AFib)
Beyond the preview
Go deeper on NCT07396519.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07396519.